(Total Views: 450)
Posted On: 01/14/2021 11:12:48 AM
Post# of 145886
Mtruong,
It appears that that guidance is only for the mAbs targeting the virus itself, so would not address leronlimab, lenzilumab and other immune modifying mAbs.
It appears that that guidance is only for the mAbs targeting the virus itself, so would not address leronlimab, lenzilumab and other immune modifying mAbs.
(2)
(0)